Declenperone is an antagonist of 5-HT2 receptors, developed by Janssen Pharmaceutica. The compound is claimed to have strong neuroleptic activity, as evidenced by experimental data obtained in apomorphine-tryptamine and norepinephrine test in rats, and the apomorphine test in dogs. Declenperone was used in a veterinary as a sedative.

Nortetrazepam is a benzodiazepine derivative, it is one of the major metabolites of tetrazepam. Nortetrazepam is a psychosedative agent.

Milenperone, a dopamine receptor antagonist was studied as an antipsychotic drug. It participated in clinical trials in the management of aggressive behavior in alcoholics and epileptics. Besides, the effect of milenperone was studied for the aggressive behavior of oligophrenic patients. However, information about the further development of the drug is not available.

Biriperone (also known as Centbutindole) was developed as an antipsychotic drug. It has shown effective antipsychotic activity in schizophrenic patients. Biriperone acts as a dopamine antagonist, and also as a blocker of 5HT(2) receptor. Clinically the drug has passed through phase I, II & III clinical trials successfully, however, the use of this drug was banned.

Emapunil acts as a selective agonist at the peripheral benzodiazepine receptor (TSPO). At the cellular level, the selective TSPO ligand XBD173 potentiated the amplitude and duration of GABA-mediated inhibitory postsynaptic currents in mouse medial prefrontal cortical neurons, which was prevented by finasteride. In animal and human trials, XBD173 produced rapid anxiolytic and anti-panic effects probably via newly synthesized neurosteroids, without producing sedation or withdrawal symptoms, and may represent a promising target for the development of fast-acting anxiolytics with a more favourable side-effect profile than benzodiazepines.

Divaplon is one of a series of imidazopyrimidine derivatives, which are benzodiazepine receptor ligands. This compound exhibits anxiolytic and anticonvulsant activity but little or no sedative/myorelaxant effects. Divaplon occupied a large percentage of benzodiazepine receptors, as measured with an in vivo binding technique, without inducing any deficit in a rotating drum task in mice, and it is suggested that divaplon is a partial agonist at GABA receptors. No significant anticonvulsant tolerance was seen with the divaplon.

Ethyl dirazepate is an anticonvulsant compound.

Nitrazepate is the diazepam derivative. Nitrazepate is tranquiliser.

Sifaprazine [FI 4303] is a substituted arylpiperazine with a similar structure to mianserin. Sifaprazine was undergoing preclinical evaluation with Ferrer in Spain as a potential antidepressant. However, no recent development has been reported.

Motrazepam (Ro06-9098) is a benzodiazepine derivative patented by a Swiss multinational healthcare company Hoffmann-La Roche as anticonvulsants, muscle relaxants, and sedative agent.